News

What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech

April 22, 2016

This week Goldman Sachs announced that its profits fell 60% in a single quarter and blamed a volatile market that’s hit it across business lines.

Continue Reading

Theranos Debacle May Scare Investors Away From Diagnostic Technology

April 13, 2016

Now that Theranos faces the prospect of a crippling ban on its operations by federal officials, let’s get past its implosion and talk about the real implications for the rest of the diagnostic sector.

Continue Reading

Why Valeant Should Be Broken Up

March 17, 2016

It’s not often that we see the collapse of a large pharmaceutical company in real time.

Continue Reading

WBB Securities Sponsors BioCentury’s 2016 Future Leaders Conference

March 1, 2016

WBB Securities is a sponsor of this year’s Future Leader’s conference.

Continue Reading

JPM 2016: Fear And Loathing In Healthcare From San Francisco

January 19, 2016

The gloom at the J.P. Morgan 34th annual healthcare conference in San Francisco last week is still thick in the air – and will likely to hover there for a while, as macro issues and falling investor confidence continue to cause problems for the U.S. pharmaceutical and biotech sector.

Continue Reading

WBB Securities Acts as Co-manager for $100 Million in Public Offering for Cempra Pharmaceuticals

January 12, 2016

WBB Securities acted as co-manager to a transaction for Cempra Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics.

Continue Reading

How Mental Health is Shortchanged by Lack of Reimbursement for Vagus Nerve Stimulation

December 30, 2015

With a continuing weekly newsfeed on the destructive conse- quences of inadequate mental healthcare and with growing data on how depression negatively impacts the ability to perform daily tasks and engage in social interactions, why does a proven therapeutic intervention for chronic depression still remain far out of reach for so many patients?

Continue Reading

Shkreli Arrested: What Happened And What Happens Next?

December 17, 2015

The arrest of Martin Shkreli for securities fraud involving alleged misuses of funds from his former company, Retrophin Inc., raises more questions than it answers–and as the case plays out in federal court this gap will only increase.

Continue Reading

Diagnosing Theranos

December 5, 2015

It couldn’t have been easy for Elizabeth Holmes, CEO & founder of the controversial blood test company Theranos, to prepare for an interview with Matt Herper at the Forbes Healthcare Summit.

Continue Reading

The Pfizer/Allergan Merger May Be Dwarfed By The Merck/Express Scripts Divide

November 23, 2015

All eyes are fixed on the declared merger of Pfizer, Inc. and Allergan plc, which has the impact of an inversion, and the questions quickly become: Is it a game changer, a challenge to Treasury’s new tax inversion guidelines, or just riveting financial drama?

Continue Reading